

EPA PSYCHOPHARMACOLOGY SECTION REPORT 2022

SECTION BOARD MEMBERS

Chairperson: Prof. Pavel MOHR

Co-chairperson: Prof. Matej STUHEC

Secretary: Dr. Lucie BARTOVA

Past-Chairperson: Prof. István BITTER

LIST OF SECTION MEMBERS:

Kollarova PATRICIE;	Robert HUNTER;	Willem Cornelis	Declan
Goran RACETOVIC;	Igor FILIPČIĆ;	Pieter GUIJT;	MCLOUGHLIN;
Jona LEWIN;	Silvana GALDERISI;	Pritam CHANDAK;	Fabian KRAXNER;
Jan LIBIGER;	Jonas EBERHARD;	Ehsan FOTOUHI	Virginio SALVI;
Hans-jürgen	Defne ERASLAN;	ARDEKANI;	Damla YILDIRIM;
MÖLLER;	Maria Paz GARCIA-	Heinz GRUNZE;	Sarfaraz Aslam
Pavel MOHR;	PORTILLA	Valentin SKRYABIN;	SHORA;
Angelika WIECK;	GONZALEZ;	Alexander	Galyna OSADCHA;
Andreja VUCHKOV;	Josep Maria HARO;	CHOMSKY;	Petra Andrea
Farzaneh	Haque MD.	Ayça CAN UZ;	SZILAGYI;
SAEEDZADEH	RASHIDUL;	Vito CAIVANO;	Anzhela BAZZAEVA;
SARDAHAEE;	Lucian - Ioan POP;	Theodoros	Marilena-petruta
Omer SAATCIOGLU;	Aleksandar SAVIC;	KOUTSOMITROS;	MAIDAN;
Janusz K.	María Isabel	Raluca STICLOSU;	Attila SZABO;
RYBAKOWSKI;	VÁSQUEZ-SUYO;	Antonio	Sumeet SINGH;
Gianluca SERAFINI;	Anthony SOARES;	METASTASIO;	Lucie BARTOVA;
Martin BRUNOVSKY;	Marisa CASANOVA	Michel NAWFAL;	Petar VIDOVIĆ;
Arie DE WERK;	DIAS;	Elena Daniela	Valentina BASILE;
Jürgen DE FRUYT;	Orkhan FARAJLI;	BUHAŞ RAMOCEA;	Raul Alberto
Joseph ADO-	Matej Stuhec;	Samuel SARRAZIN;	CORTES LADINO;
IMOISILI;	Milos MILUTINOVIC;	Andriy V.	Rebecca WARD;
István BITTER;	Amro SOLIMAN;	SAMOKHVALOV;	Şengül ŞAHIN;
Julio BOBES;	Patrick BRIGGS;	Laura ORSOLINI;	Sara RODRIGUES;
Jacques A.j.	Sundar GNANAVEL;	Maria FILIP;	Badii AMAMOU;
BOERMANS;	Dalibor KARLOVIC;	Aiste LENGVENYTE;	Herta AGAJ;
Pierre BAUMANN;	Richard SYKES;	Shahzain HASAN;	Madalina-claudia
Luiz DRATCU;	Octavian VASILIU;	Joshua RODRIGUEZ;	NEACSU;
René Sylvian KAHN;	Rodrigo DA GRAÇA	Süreyya AKYILDIRIM	Irene PINUCCI;
Cyril HÖSCHL;	SANTOS;	COR;	Marek JAREMA;
Volodymyr	Ivan KOYCHEV;	Aram	
KOROSTIY;	Nikola ŽAJA;	MAMIKONYAN;	
Siegfried KASPER;	Zhuchenko IHOR;	Raul Felipe PALMA	
Ozge KILIC;	Beomwoo NAM;	ALVAREZ;	

LAST SECTION COMMITTEE ELECTIONS HELD:

Date: 27 May 2022

Venue: online

ACTIVITIES OF THE SECTION IN 2022:

Meetings/events

Psychotropic Drug Approvals Were Not Based on ICD-11: How to Treat Disorders Newly Defined in ICD-11?

Description:

Chair(s): Pavel Mohr (Czech Republic) István Bitter (Hungary)

1. ICD-11 Primary Psychotic Disorders: What is New and May be Relevant for Treatment Selection and Outcome? Presenter Wolfgang Gaebel (Germany)
 2. Treating Catatonia: a Blind Spot of Psychiatry? Presenter Pavel Mohr (Czech Republic)
- EPA PSYCHOPHARMACOLOGY SECTION REPORT 2022
3. Neurodevelopmental Disorders in Adulthood: ADHD and ASD. Presenter J. Antoni R. QUIROGA (Spain)
 4. Approved Indications vs. New Diagnostic Categories: Regulator's Point of View. Presenter Agnes Gyurasics (Hungary)

Summary:

In 2019, the WHO has adopted the 11th revision of the International Classification of Diseases (ICD-11), with planned implementation from 2022 onwards. The chapter Mental, Behavioural or Neurodevelopmental Disorders in ICD-11 expands the number of categories, modifies terminology, and includes new diagnostic entities. Major change is a separation of Sleep- wake disorders and Sexual dysfunctions, Sexual pain disorders, and Gender incongruence into individual chapters. Although the impact of ICD-11 on clinical practice is yet to be examined, it is clear that treatment guidelines should be adjusted accordingly. Thus, it is urgent to determine the availability of approved treatments for new disorders, to look into the labels of psychotropic drugs based on classifications before ICD-11 and to determine how they fit into the new system.

The symposium will focus on several clinically relevant groups of mental disorders that changed from the previous classification: psychotic disorders, neurodevelopmental disorders, eating disorders, and catatonia, which has been introduced into ICD-11 as an independent category. Available treatment options and therapeutic strategies for the updated classification will be discussed.

Location: EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

Start date: 04/06/2022

End date: 04/06/2022

Pharmacological Treatment of Elderly Patients with Comorbid Mental and Somatic Diseases

Description:

Pharmacological Treatment of Elderly Patients with Comorbid Mental and Somatic Diseases, Sun, 05.06.2022

Chair(s): Matej Stuhec (Slovenia) Cécile Hanon (France)

Organised by the EPA Sections on Old Age Psychiatry and Psychopharmacology.

1. Epidemiology and Pharmacoepidemiology of Comorbidities in Patients with Mental Disorders.

Presenter István Bitter (Hungary)

2. General principles of pharmacotherapy selection in elderly patients for different comorbidities.

Presenter Matej Stuhec (Slovenia)

3. Treatment of Insomnia in Multimorbid Elderly. Presenter Gabriela Stoppe (Switzerland)

4. Pain Medication in the Elderly Patient. Presenter Florian Riese (Switzerland)

5. Treatment of Somatic Comorbidities in the Elderly with Mental Disorders. Presenter Igor Filipcic (Croatia)

Location: EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

Start date: 05/06/2022

End date: 05/06/2022

Psychopharmacology of Antipsychotics in Schizophrenia

Description:

EPA Course 11: Psychopharmacology of Antipsychotics in Schizophrenia

Sun, 05.06.2022

Course Director: István Bitter, Hungary

Course Co-Director: Matej Stuhec, Slovenia

Organised by the EPA Section on Psychopharmacology.

This interactive, evidence-based course has been designed for early career psychiatrists, however other colleagues – especially those, who teach/supervise residents – also may benefit from the structured teaching material. The content of the course is primarily built on landmark studies and the data which will be discussed includes real world evidence as well. The participants should be able after completing the course to individually plan antipsychotic treatment for patients with schizophrenia and with some other psychotic disorders. The course will have a clinical focus and includes the following topics: • Short- and long-term treatment of schizophrenia with antipsychotics • Dose response relationship of antipsychotic drugs: How to define the right dose? Is there a therapeutic window? How do patients benefit from the use of therapeutic (plasma level) drug monitoring? • How to choose from different formulations of antipsychotics, e.g. different tablet forms, solution, rapid acting and long acting injectable (LAI) antipsychotics? • Comparative effectiveness of antipsychotics • Pharmacological treatment of negative symptoms in schizophrenia • The role of antipsychotics and other drugs in the management of agitation, suicidal and violent behaviour in schizophrenia • Partial response, non – response and treatment resistance: Antipsychotic monotherapy vs. polypharmacy and the role of clozapine treatment • Possible treatment strategies to avoid antipsychotic polypharmacy • Length of antipsychotic treatment in schizophrenia; how to discontinue antipsychotic treatment; risks of

antipsychotic withdrawal • Antipsychotic treatment in the elderly: schizophrenia and psychosis related to dementia • Management of the most frequent side effects and drug-drug interactions during treatment with antipsychotics.

Location: EPA Congress. The 30th European Congress of Psychiatry, 4-7 June 2022, Budapest (Hungary)

Start date: 05/06/2022

End date: 05/06/2022

Section meeting

Location: Virtual

Start date: July 2022

End date: July 2022

Publications

Mental Health Research and Practice: from evidence to experience. Psychopharmacology chapter – EPA.

Journal: Book Chapter, Cambridge University Press

Authors: Pavel Mohr, Matej Stuhec, István Bitter

(Expected) Publication date: 01/03/2022

Acknowledged as official Section publication? Yes

FUTURE ACTIVITIES:

The section plans the following activities in 2023:

InterACT e-newsletter

Symposia, workshop and course

EPA Congress. The 31st European Congress of Psychiatry, 25-28 March 2023, Paris (France)

Symposium: How to prevent first onset and relapse of serious psychiatric diseases

This is a joint symposium with the section of Prevention of Mental Disorders that has already been accepted.

Chair: Pavel Mohr (Czechia)

Co-Chair: Andrea Raballo (Italy)

1. Pharmacotherapy of high-risk population for developing psychosis. Presenter: Pavel Mohr (Czechia)
2. Onset and relapse prevention of bipolar disorders. Presenter: Eduard Vieta (Spain)

3. Prevention strategies in clinical high-risk states for psychotic disorders: weighing up costs and benefits? Presenter: Frauke Schultze-Lutter (Germany)

4. Pharmacological treatment at early psychosis: risks and benefits. Presenter: Liene Sile (Latvia)
Annotation:

The symposium will address the issue of prevention of serious mental disorders, with focus on high-risk individuals for developing severe psychiatric illnesses (primary indicated prevention) and patients with relapsing course of disorder (tertiary prevention). We will review and discuss the evidence of pharmacological, psychological or other non-pharmacological strategies in preventing new illness onset and reducing risk of relapse and functional decline. Thereby, the focus will be especially on the clinical high-risk samples for developing and patient samples at risk for redeveloping psychotic or bipolar disorder. Critically evaluating costs and benefits of the different intervention strategies, the symposium will provide clinicians with a basis for a well-informed decision on preventive strategies for both first onset and relapse of psychotic and bipolar disorders.

EPA Congress. The 31st European Congress of Psychiatry, 25-28 March 2023, Paris (France)

Course: A practice oriented intensive course on pharmacological treatment of schizophrenia and some other disorders

Organised by the EPA Section of Psychopharmacology. Chairs: István Bitter, Hungary & Matej Stuhec, Slovenia

EPA Online Talks With Experts meeting

- Collaboration with the EPA Section "Early Career Psychiatrists (ECP)"

The project format (<https://www.europsy.net/online-talks-with-experts/>) involves a 15-minute presentation by an expert and 45 minutes of questions and answers by an audience of ECPs from Europe (moderated by the EPA Committee Members of both sections: Psychopharmacology and ECP). The planned time for the session is April 2023 (after the EPA Congress 2023).

This proposed session is thought to help ECPs in Europe to improve their clinical practice and knowledge of psychopharmacology.

FUNDING IN 2022

Income: None

Source(s) of funding: None

Expenditure: None

Balance: None

EPA Treasurer audit: No

Confirmation that income / expenditure is via EPA: No